ClinicalTrials.gg
CompletedNCT04616807Updated Jun 22, 2026

An Observational Study in Adult Patients With Non-dystrophic Myotonic Disorders

An observational study in Myotonic Dystrophy, sponsored by Lupin Ltd.. Completed at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Lupin Ltd. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
53
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Myotonic Dystrophy with a site in France — 10 open to participants now, 13 under way, 4 of them phase 3. Myotonic Dystrophy · France.

Enrollment
7th of 10
53 · median 79
Started
2020
with 2 others
Observational
10 of 30
2 open now
Registered
13th of 30
by date
Lead sponsor
3 of 30
Lupin Ltd.

Among the 30 studies in Myotonic Dystrophy with a site in France, this one is the 7th largest by enrollment of the 10 observational ones that give a count, is one of 3 that started in 2020, is one of 10 observational ones, and was the 13th registered.

Myotonic Dystrophy

127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.

Browse Myotonic Dystrophy studies →

Open to participants now

10 of the 30 studies in Myotonic Dystrophy with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Myotonic Dystrophy with a site in France, or all of them as a file.
02

Study summary

This is a non-interventional, prospective, observational, multicentre study to evaluate the long-term safety and effectiveness of Namuscla in adult patients with NDM.

Read the detailed description

This is a non-interventional, prospective, observational, multicentre study to evaluate the long-term safety and effectiveness of Namuscla in adult patients with NDM. Namuscla should be prescribed as per the approved Summary of Product Characteristics (SmPC).

Adult patients with non-dystrophic myotonic disorders who have been prescribed Namuscla by the treating physician, and who meet the eligibility criteria will be enrolled in this study.

This includes:

  • Patients newly initiated on Namuscla for the treatment of NDM (newly exposed)
  • Patients already on Namuscla/ mexiletine at enrolment - For patients receiving mexiletine other than Namuscla, only those who switch to Namuscla will be included in the study.

Patients already being treated with Namuscla/ mexiletine at the time of enrolment will be considered for enrolment provided they meet the eligibility criteria.

The study will be initiated at specialized centres for the treatment of myotonic disorders ("reference centres") in the United Kingdom (UK), France, and Germany, depending on availability of Namuscla in the specific country. Depending on the enrolment and marketing status (availability) of Namuscla in other countries in the EU, inclusion of additional sites in other countries will be considered.

The study population will comprise patients who are diagnosed with non-dystrophic myotonic disorders and considered suitable candidates for the treatment by Namuscla by the investigators according to the approved SmPC. Patients will be enrolled over an approximate 2-year enrolment period and will be followed-up on-treatment for up to 3 years. Each enrolled patient will be observed for 3 years or until discontinuation (if discontinued early).

For all enrolled patients, the baseline would be the latest data available at the enrolment visit.

For the patients already on Namuscla, cumulative data (data related previous exposure as well as current data) will be collected for adverse events (AEs) on Namuscla treatment.

No drug will be supplied for this study; patients will receive medicines through local standard practices. All evaluations and investigations during the study will be performed according to the routine clinical practices and discretion of the treating physician.

03

Conditions studied

  • Myotonic Dystrophy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

The study will target the enrolment of 50 patients who are treated with Namuscla.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult, male or female patients with non-dystrophic myotonic disorders planned to be started on Namuscla according to the approved SmPC
  2. Patients already receiving Namuscla/mexiletine for the treatment of NDM; (for patients on mexiletine other than Namuscla, only those who switch to Namuscla will be enrolled).
  3. Patients who understand and are willing to provide .

Exclusion criteria

Exclusion Criteria:

  1. Patients who are enrolled or participating in any other clinical trial for an product. -
  2. to mexiletine, or to any of the of Namuscla, or hypersensitivity to any local anaesthetic
  3. Ventricular tachyarrhythmia
  4. Atrial tachyarrhythmia, fibrillation or flutter
  5. Complete heart block (ie, third-degree atrioventricular block) or any heart block susceptible to evolve to complete heart block (first-degree atrioventricular block with markedly prolonged PR interval (≥ 240 ms) and/or wide QRS complex (≥ 120 ms), second-degree atrioventricular block, bundle branch block, bifascicular and trifascicular block),
  6. Myocardial infarction (acute or past), or abnormal Q-waves
  7. Symptomatic coronary artery disease
  8. Heart failure with reduced \<50%
  9. Sinus node dysfunction (including sinus rate \< 50 bpm)
  10. Patients receiving drugs that can induce torsades de pointes
  11. Patients receiving medicinal products with narrow therapeutic index (ie, theophylline, tizanidine, digoxin, lithium, phenytoin or warfarin)
  12. Patients who are pregnant or lactating.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
53 participants (actual)
Patient registry
No

Interventions

  • Observational Study

    Also known as: Namuscla ™

06

What researchers measure

Primary outcomes

  1. Primary Outcome 1 Proportion of patients with treatment-emergent AEs

    Proportion of patients with treatment-emergent AEs (\[TEAEs\], including SAEs) from study enrolment to 6, 12, 24 and 36 months on Namuscla

    Time frame: Approximately 3 years

  2. Primary Outcome 2 Proportion of patients requiring dose reduction or treatment discontinuation

    Proportion of patients requiring dose reduction or treatment discontinuation due to AEs (including SAEs).

    Time frame: Approximately 3 years

Secondary outcomes

  1. Secondary Outcome Proportion of patients with AEs /SAEs/ Adverse Event of Special Interest (AESI)

    Proportion of patients with AEs /SAEs/ Adverse Event of Special Interest (AESI) from study enrolment to 6, 12, 24, and 36 months

    Time frame: Approximately 3 years

07

Study locations

6 sites
  • Hôpital Universitaire de La Pitié Salpêtrière
    Paris, Cedex 13 75013, France
  • CHRU Lille
    Lille, 59000, France
  • St. Josef-Hospital Klinikum der Ruhr Universitaet Bochum
    Bochum, North Rhine-Westphalia 44791, Germany
  • Universitätsklinikum Ulm, Klinik für Neurologie
    Ulm, 89081, Germany
  • Institute of Neurology
    London, England WC1N 3BG, United Kingdom
  • Nottingham University Hospitals NHS Trust
    Nottingham, England NG7 2UH, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Jan 2026, 60 months.

Of 36 observational studies under Myotonic Dystrophy, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35. This study's 60 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2020
First posted
Nov 5, 2020
StartActual
Dec 17, 2020
Primary completionActual
Jan 16, 2026
CompletionActual
Jan 16, 2026
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04616807
Lead sponsor
Lupin Ltd.
Responsible party
Sponsor
First posted
Nov 5, 2020
Start date
Dec 17, 2020
Primary completion
Jan 16, 2026
Completion
Jan 16, 2026
Last update
Jun 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion